tbuckley/cabot-search huggingface dataset:
QLIF-17. THE IMPORTANCE OF THE CERN FOUNDATION ADULT EPENDYMOMA OUTCOMES PROJECT
Authors: Alvina A. Acquaye, Elizabeth Vera, Mark R. Gilbert, Terri S. Armstrong
Journal: Neuro-Oncology (2016)

Outcomes projects can be a catalyst in determining disease and treatment-related consequences for patients with rare tumors and in identifying ways to educate patients and providers. The Adult Ependymoma Outcomes (AEO) survey uses self-reported experiences to evaluate how this tumor impacts patients throughout their illness. Patients completed the AEO survey via web-based portal. The survey includes questions on treatment, tumor recurrence, current health status, the MD Anderson Symptom Inventory-Brain and Spine Module and the MOS 36-Item Short Form Health Survey.The sample included 264 participants (female=54%), with a median age of 46 (18-77), who were married (65%) with at least a college education (37%). Radiation treatment was more commonly used in patients with brain involvement (Χ2 (1) =20.7, p<0.001), who underwent a partial resection (21%, Χ2 (3) =15.4, p<0.001), or with a grade 3 tumor (13%, Χ2 (2) =18.8, p<0.001). Recurrence occurred in a small group (29%), with Grade 1 tumor patients 2.6 times and Grade 3 tumor patients 2.5 times more likely to have recurrence compared to those with Grade 2 tumors. Spine tumor patients had a higher symptom burden (mean=2.8; scale 0 to 10) than brain tumor patients (mean=1.9, t (247) =-4.0) and reported more moderate to severe symptoms (rating ≥ 5) (29%) compared to their counterparts (18%). Within physical health of the SF-36, spine patients reported worse health in bodily pain (mean=49.1, v mean=72.1, t (249) =6.8 p<0.001), physical functioning (mean=51.6, v mean=67.8, t (252) =4.1, p<0.001), and vitality (mean=40.9, v mean=50.1, t (202.2) =3.0, p<0.003). These results demonstrate the feasibility in implementing outcome projects that report on the clinical and demographic characteristics of a rare patient population and underscore the importance of outcomes data in understanding disease-related issues. This also supports future studies focusing on specific areas that can potentially improve aspects patient care and overall well-being.
Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)
Authors: E. Efstathiou, A. Tsikkinis, S. Wen, E. Li Ning Tapia, A. Hoang, A. Aparicio, S.-M. Tu, G. Rangel, P. Troncoso, P. Corn, J. Araujo, C. Logothetis
Journal: Annals of Oncology (2016)
Targeting Casein Kinase II Exerts a Therapeutic Effect in Pediatric High Risk Leukemia Via Inhibition of Cell Cycle Progression and the PI3K Pathway
Authors: Chandrika S. Gowda, Chunhua Song, Yali Ding, Sunil Muthusami, Kimberly Payne, Zheng Ge, Sinisa Dovat
Journal: Blood (2015)
Florida dermatologist who falsely diagnosed hundreds of cancer cases gets $18m fine
Authors: Owen Dyer
Journal: BMJ (2017)

A Florida dermatologist who falsely told hundreds of his patients that they had skin cancer so he could bill for unnecessary treatments, including radiation, must pay $18m (£14.5m; €17m) to settle fraud claims made against him by the US government and a whistleblowing local doctor.

But his clinic is still open and his license is active, and there is no sign of a disciplinary case before the state’s medical board.

Gary Lee Marder, 60, owns the Allergy, Dermatology and Skin Cancer Center, a clinic in Port St Lucie, Florida.

No precise figures are available for the number of misdiagnoses he made or the total for which he fraudulently billed Medicare, but the volume was high. A physician co-defendant in the case, pathologist Robert Kendall, was sent roughly 35 000 biopsy samples from Marder’s clinic from 2008 to 2014 in what government lawyers called a kickback scheme. Kendall agreed to pay $250 000 to settle claims against him.

Marder urged his physician assistants to each perform 50 biopsies a day, …
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma
Authors: H Inoue, M Hashimura, M Akiya, R Chiba, M Saegusa
Journal: Molecular Cancer (2017)

Anaplastic lymphoma kinase (ALK), which is a receptor tyrosine kinase, is essentially and transiently expressed in the developing nervous system. Recently, the deregulated expression of full-length ALK has been observed in some primary solid tumors, but little is known about its involvement in the tumorigenesis of uterine carcinosarcomas (UCSs). Here we examined the functional role of the ALK gene in UCSs.
Cost-effectiveness of predictive markers in breast cancer: An analysis from a Swiss perspective
Authors: P. R. Blank, M. Schwenkglenks, B. C. Pestalozzi, H. Moch, T. D. Szucs
Journal: Journal of Clinical Oncology (2009)

6578 Background: Breast cancer has one of the highest cancer related death rates all over the world. New therapeutic agents like trastuzumab have yielded significant clinical benefits in human epidermal growth factor receptor 2 (HER-2) overexpressing tumors, but have also increased costs substantially. A cost-effectiveness analysis was performed to estimate the economic implications of testing HER-2-status in breast cancer patients. Methods: A Markov state transition model was used to assess the costs and effectiveness of a hypothetical cohort of 10,000 females at the age of 50 years. Probabilities for recurrence and cancer related death have been derived from published trials. The model was run life-long (i.e., for 50 years). Incremental costs were evaluated for diagnostic tests and treatments in both the HER-2 tested and the untested arm. Costs were estimated using data from a third party payer prospective in Switzerland. Results: Predictive testing with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) accounted for €48 and €312, respectively. The costs for trastuzumab administration for a one year treatment summed up to €38,716 per patient. The life-long Markov model resulted in a total cost difference of €-17,774 in favor of the predictive test strategy. No difference in regard to the effectiveness was evident, yielding in 9 QALYs gained at the end of the modeling cycle for both strategies. The dominance of the testing regimen implied the analysis of the planned cost-effectiveness ratio being superfluous. The model showed robustness for variable variations in the deterministic sensitivity analysis. The probabilistic sensitivity analysis revealed no impact on parameter uncertainties of the model results. The position of the HER-2 testing group was never non dominant. Conclusions: Predictive tests for HER-2-status offer an economically favorable approach to identify patients deriving benefit from trastuzumab treatment. Over a life-long horizon, our model predicts confirms that the usage of HER-2 tests is the dominant strategy. The outcome was robust to changes in the model assumptions. Economically as well as clinically, using HER-2 testing is the preferred strategy in the direction to personalized cancer care. No significant financial relationships to disclose.
Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients
Authors: Pervin Topcuoglu, Pinar Ataca, Sinem Civriz Bozdag, Selami Kocak Toprak, Onder Arslan, Muhit Ozcan, Taner Demirer, Nahide Konuk, Hamdi Akan, Osman Ilhan, Meral Beksac, Gunhan Gurman
Journal: Blood (2014)
P08.33 GLIOSTRY (Glioblastoma Registry) of the AINO (Italian Association of Neuro-Oncology): final analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first progression following chemoradiation.
Authors: R. Rudà, G. Lombardi, S. Scoccianti, F. Pasqualetti, A. Silvani, A. Pace, M. Arcicasa, M. Salvati, M. Caroli, R. Soffietti
Journal: Neuro-Oncology (2016)
Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).
Authors: Dong Hwan (Dennis) Kim, Gizelle Popradi, John Kuruvilla, Vikas Gupta, Mark Minden, Hans A. Messner, Jeffrey H. Lipton
Journal: Blood (2007)
A population-based study of metastatic colorectal cancer (mCRC) in people age 80 and older: Findings from the South Australian Clinical Registry (SACR) for mCRC.
Authors: K. Jain, C. Beeke, T. J. Price, G. P. Young, D. Roder, R. Padbury, A. R. Townsend, A. Richards, C. S. Karapetis
Journal: Journal of Clinical Oncology (2011)

514 Background: Life expectancy is increasing and more patients (pts) with mCRC are presenting at an advanced age (&gt;80). Optimal management approach for this group of pts is not well defined as they are under-represented in clinical trials. Methods: The SACR for mCRC collects data on mCRC pts diagnosed after 1/2/2006. We examined cancer characteristics, treatments administered and outcomes for pts aged &gt;80 yrs. Comparison was made with pts &lt;80 yrs. Results: Data from 1737 mCRC pts has been entered to date of which 522 (30%) pts were aged ≥ 80. Key patient characteristics and treatments are reported in the table. The majority had grade 2 tumours. Grade 3 differentiation was reported in lower proportion of pts ≥80 yrs than the younger group (18% v 26%, p &lt; 0.001). Only 23.6% of pts &gt;80 received chemotherapy (CT). Of these, 63% received single agent CT (mostly capecitabine) while 37% received combination CT as first line treatment. In contrast, 67% of pts &lt;80 received CT, 73% of which received combination CT and 27% single agent (majority capecitabine) as their first line CT. Pts aged ≥ 80 had fewer liver resections and were also less likely to receive radiotherapy or monoclonal antibodies. Median survival was 7.1 mths for &gt;80 yrs v 17.4 mths for &lt;80 yrs, p &lt; 0.001. Median survival for pts treated with chemotherapy was 19 mths for &gt;80 and 21.7 mths for &lt;80, p = 0.141. Pts without any treatment had a poor survival regardless of their age (median survival 2.9 mths &gt;80 yrs v 2.4 mths &lt;80 yrs). Conclusions: Older pts (≥ 80 yrs) were less likely to receive intervention for their mCRC and had poorer survival. However, survival for selected elderly pts, who received CT, was similar to those &lt;80, despite most receiving single agent therapy. [Table: see text] [Table: see text]
OS01.3 mtTERT promoter as a target for treatment of Glioblastoma
Authors: H. Dhruv, S. Bollam, H. Kang, S. Peng, V. Gokhale, L. Hurley, M. Berens
Journal: Neuro-Oncology (2017)

Approximately 86% of GBM tumors exhibit mutation at -124 or -146 bases upstream of the ATG start site in the transcription activating promoter region of Human telomerase reverse transcriptase (hTERT). Mutation in the promoter region of hTERT impairs repression, leading to overexpression of hTERT; inappropriate hTERT is associated with oncogenesis, tumor maintenance, and resistance to apoptosis. We surveyed long-term glioma cell lines and glioma PDX models for mt-hTERT; mRNA and protein expression of hTERT were assessed by qPCR and western blot. The -124 and -146 mutations are located in the major 5–12 G-quadruplex and result in misfolding of the silencer element and consequent over-expression of hTERT. Using a diverse small molecule library, we identified a small drug-like pharmacological chaperone (pharmacoperone) molecule, TG-4260, which binds to the 26 mer base-pair heteroduplex loop, which is the nucleation site for cooperative folding of the major 5–12 G-quadruplex. The chaperone effect of TG-4260 corrects DNA hTERT G-quadruplex misfolding resulting from the somatic mutations and restores the silencer function of the G-quadruplex thereby reducing hTERT activity. TG-4260 directly decreases the transcription activity of the WT and the −124, −124/125, −138/139, and −146 mutants to a similar extent and suppresses the downstream gene BCL2, which activates caspase-3 and produces cell-cycle arrest, leading to cell death. Finally, TG-4260 significantly inhibits telomerase and shortens telomere length after five days of treatment and induces a senescence-like phenotype. This is the first example of the use of a pharmacoperone molecule to correct the misfolding of a DNA G-quadruplex element resulting from mutations in an early folding intermediate. Finally, we screened GBM cell models against a novel small molecule inhibitor that interferes with mutated hTERT promoter and demonstrated that TG-4260 selectively suppresses glioma cell viability without affecting non-transformed normal human astrocytes.
Sirolimus and GvHD Control: the Rhesus Macaque GvHD Model Reveals That Sirolimus Preferentially Inhibits T Cell Proliferation While Permitting Breakthrough T cell Activation After MHC-Mismatched Hematopoietic Stem Cell Transplantation
Authors: Karnail Singh, Swetha Srinivasan, Angela Panoskaltsis-Mortari, Sharon Sen, Kelly Hamby, Taylor Deane, Linda Stempora, Frank Leopardi, John Shires, Jonathan Beus, Benjamin Byrd, Bruce R. Blazar, Leslie Kean
Journal: Blood (2010)
Genomic instability and early-onset colorectal cancer: a new form of classifying the disease?
Authors: M. Arriba, J.L. García, J.M. Cano, D. Rueda, J. Pérez, L. Brandariz, T. Fernández, O.A. Nutu, L. Alonso, M. Urioste, R. González-Sarmiento, J. Perea
Journal: Annals of Oncology (2016)
HER2 activation and epithelial-mesenchymal transition (EMT) are involved in the acquired resistance to cetuximab in combination with either regorafenib or refametinib
Authors: P.P. Vitiello, G. Martini, V. Belli, C. Cardone, V. Sforza, M.L. Ferrara, S. Napolitano, C.M. Della Corte, N. Zanaletti, P. Vitale, L. Pompella, F. Morgillo, T. Troiani, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2016)
Cell Autonomous Defects of Mesenchymal Stem Progenitor Cells of Patients with CMML Contribute to Impaired Hematopoietic Supportive Activity
Authors: Hui Shi, Rong Li, Wen Xing, Jie Bai, Xiaohui Si, Mingjiang Xu, Yuan Zhou, Feng-Chun Yang
Journal: Blood (2015)
Molecular Alterations in Bone Marrow Mesenchymal Stroma Cells of AML Patients
Authors: Eva von der Heide, Sebastian Vosberg, Martin Neumann, Liliana H. Mochmann, Alva Rani James, Jutta Ortiz Tanchez, Cornelia Schlee, Konstandina Isaakidis, Marlene Luther, Alexander Graf, Stefan Krebs, Helmut Blum, Wolf-Karsten Hofmann, Philipp A Greif, Claudia D Baldus
Journal: Blood (2014)
Targeting YAP-dependent MDSC infiltration impairs tumor progression
Authors: Guocan Wang, Xin Lu, Prasenjit Dey, Pingna Deng, Chia Chin Wu, Shan Jiang, Zhuangna Fang, Kun Zhao, Ramakrishna Konaparthi, Sujun Hua, Jianhua Zhang, Elsa M Li Ning Tapia, Avnish Kapoor, Neelay Patel, Zhenglin Guo, Vandhana Ramamoorthy, Trang Tieu, Tim Heffernan, Di Zhao, Xiaoying Shang, Sunada Khadka, Pingping Hou, Baoli Hu, Qing Chang, Patricia Troncoso, Christopher Logothetis, Mark McArthur, Lynda Chin, Y Alan Wang, Ronald DePinho
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Myeloid-derived suppressor cells (MDSCs) represent a phenotypically heterogeneous population of immature myeloid cells that play a tumor-promoting role by maintaining a state of immunological anergy and tolerance. Similar to other solid tumor types, Prostate cancer (PCa) is
EXTH-57. INTERACTION OF 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN) WITH MELANOMA MELANIN METABOLISM AND CELL DEATH
Authors: Lee Roy Morgan, Mansour Mathkour, Juanita Garces, Edmund N. Benes, Andrew H. Rodgers, Brando S. Jursic, R.F. Struck, W.R. Waud, Philip Friedlander, Roy Weiner, Marcus Ware
Journal: Neuro-Oncology (2016)
Paxillin: a crossroad in pathological cell migration
Authors: Ana María López-Colomé, Irene Lee-Rivera, Regina Benavides-Hidalgo, Edith López
Journal: Journal of Hematology & Oncology (2017)

Paxilllin is a multifunctional and multidomain focal adhesion adapter protein which serves an important scaffolding role at focal adhesions by recruiting structural and signaling molecules involved in cell movement and migration, when phosphorylated on specific Tyr and Ser residues. Upon integrin engagement with extracellular matrix, paxillin is phosphorylated at Tyr31, Tyr118, Ser188, and Ser190, activating numerous signaling cascades which promote cell migration, indicating that the regulation of adhesion dynamics is under the control of a complex display of signaling mechanisms. Among them, paxillin disassembly from focal adhesions induced by extracellular regulated kinase (ERK)-mediated phosphorylation of serines 106, 231, and 290 as well as the binding of the phosphatase PEST to paxillin have been shown to play a key role in cell migration. Paxillin also coordinates the spatiotemporal activation of signaling molecules, including Cdc42, Rac1, and RhoA GTPases, by recruiting GEFs, GAPs, and GITs to focal adhesions. As a major participant in the regulation of cell movement, paxillin plays distinct roles in specific tissues and developmental stages and is involved in immune response, epithelial morphogenesis, and embryonic development. Importantly, paxillin is also an essential player in pathological conditions including oxidative stress, inflammation, endothelial cell barrier dysfunction, and cancer development and metastasis.
Abstract 18021: Functional Substrates as the Strongest Predictor of Outcomes in Patients Presenting for Ventricular Arrhythmia Ablation
Authors: Justin Hayase, Yonatan Faiwiszewski, Stephen Vampola, Aron Bender, Gordon Ho, Tina Baykaner, Gautam Lalani, Amir Schricker, Wouter-Jan Rappel, Sanjiv Narayan, David Krummen
Journal: Circulation (2015)

Introduction: Recent work has shown that rotor characteristics can distinguish sustained versus non-sustained ventricular fibrillation (VF). However, the significance of functional VF substrates on patient outcomes is not studied. Methods: In 26 consecutive patients presenting for ventricular arrhythmia ablation procedures, 64-electrode basket catheters were inserted into both the left and right ventricles and VF was induced and defibrillated at 11±3 seconds. Computational phase analysis was performed and each VF cycle was characterized as rotor, focal, or disorganized activation. Follow-up data were analyzed for arrhythmia recurrence and compared to rotor stability. Forward stepwise regression analysis incorporating age, history of CHF, history of a-fib, history of prior MI, number of VTs induced, and presence of post-procedure inducible VT was performed to determine the strongest predictor of procedural outcome. Results: Of 26 patients, 19 had sustained VF, and 16 underwent attempted ablation (7 VT, 9 PVC). Optimization of the Youden index for the ROC analysis regarding rotor stability and procedural outcome demonstrated that maximum rotor stability of &gt; 14.5 rotations (corresponding to total rotor prevalence of 71%) provided optimal sensitivity of 85% and specificity of 87% for arrhythmia recurrence. Among these, greater rotor stability was significantly associated with ventricular arrhythmia recurrence (86% versus 11%, p = 0.01) (Table 1), and was the strongest predictor of outcomes. Recurrence was independent of presenting arrhythmia. Conclusions: Functional VF/VT metrics were the strongest predictor of ventricular arrhythmia outcomes compared to traditional predictors in this series of patients. This suggests that functional substrate characteristics may provide added insight into recurrence mechanisms. Whether they may identify a target for future interventions requires further study.
Multiple Endocrine Neoplasia Type 2B Unmasked by 18 F-FDG PET/CT and 131 I-MIBG SPECT/CT
Authors: Xun Sun, Maher Mohamad Rajab Arnous, Xiaoli Lan
Journal: Clinical Nuclear Medicine (2017)

F-FDG PET/CT was performed to detect an occult malignancy in a 26-year-old woman with complicated medical history which included paroxysmal hypertension and significantly elevated tumor marker. The images revealed lesions in the thyroid, lymph nodes, and bilateral adrenal glands. Further I-MIBG SPECT/CT revealed intense activity in the lesion in the left adrenal gland, which was consistent with pheochromocytoma. The pathology examination after subsequent neck biopsy demonstrated medullary thyroid carcinoma. A diagnosis of multiple endocrine neoplasia type 2B was eventually made.
MPTH-54. DIFFERENTIAL PD-L1 EXPRESSION IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMAS
Authors: Wenyin Shi, Nneamaka Nwaoduah, David Andrews, Kevin Judy, James Evans, Christopher Farrell, Lawrence Kenyon
Journal: Neuro-Oncology (2016)

PD-L1 expression is positively correlated with response to PD-1 inhibitors in non-CNS tumors. The reported incidence of PD-L1 expression in glioblastoma is relatively high. However, it is unknown if PD-L1 expression changes between initial diagnosis and upon recurrence. We identified 13 patients who had surgical resection for recurrent glioblastoma, whose specimens from initial diagnosis were also available for analysis. The PD-L1 staining was performed by Caris Life Sciences (Phoenix, AZ). The slides were scanned at 20x on the Aperio Scan Scope XT (Leica, Buffalo Grove, IL) and automatic scores with percentage of positive staining were generated. All specimens were then examined by a neuro-pathologist. Cases containing more than 0.1% 2+ or 3+ staining confirmed by visual examination were considered positive. PD-L1 expression in the paired specimens was compared. 10 of the 13 (77.0%) patients had positive PD-L1 staining (2+) at initial diagnosis, and 9 of 13 patients (70%) had positive PD-L1 staining at time of recurrence. The median percentage of positive cells was low, 0.15% in specimens from initial diagnosis, and 0.25% in specimens from recurrent tumors. Only 6 (46%) patients had positive PD-L1 staining at both initial diagnosis and recurrence. 4 (30.7%) patients that were initially positive for PD-L1 staining were negative at the time of recurrence, and 3 (23.1%) patients with negative PD-L1 staining at initial diagnosis stained positive at the time of recurrence. PD-L1 stained positive cells were detected in a high percentage of patients with glioblastoma. However, the percentage of positive cells was low. There was significant differential PD-L1 expression between initial diagnosis and recurrence. Further evaluation with a larger sample size is needed to confirm this finding.
E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx)
Authors: A. Ferrari, Y.-H. Chen, G. Hudes, M. Carducci, E.S. Antonarakis, N.M. Hahn, H. Ma, Y.-N. Wong, T. Mayer, R.A. Somer, B. Carthon, R. Dipaola
Journal: Annals of Oncology (2016)
Phosphorylation of PKM2 by NPM-ALK Regulates a Metabolic Shift and Increased Oncogenic Potential
Authors: Scott RP McDonnell, Steven R Hwang, Venkatesha Basrur, Kevin Conlon, Damian Fermin, Carlos Murga-Zamalloa, Delphine C.M. Rolland, Craig J. Thomas, Kojo SJ Elenitoba-Johnson, Megan S. Lim
Journal: Blood (2012)
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Authors: R. Rai, J.L. McQuade, D.Y. Wang, J.J. Park, K. Nahar, J.A. Sosman, K.E. Beckermann, L.E. Haydu, S. Lo, S. Rubinstein, K.E. Beckermann, M. McKean, S. Matthew, A. Guminski, M.S. Carlino, M. Davies, D.B. Johnson, G.V. Long, A.M. Menzies
Journal: Annals of Oncology (2016)
CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematological Malignancies.
Authors: Frits VanRhee, Luis Fayad, Hossein Borghaei, Peter M. Voorhees, Robert Z. Orlowski, Richard R. Furman, Mohamed Zaki, Uma Prabhakar, Trina Jiao, Christine Lihou, Carlos A. Garay, Razelle Kurzrock
Journal: Blood (2006)
P15 and P16 Promoters Methylation Status in APL Patients Treated by Arsenic Trioxide.
Authors: Omid Yeganeh, Kamran Alimoghaddam, Seyed Hamidolah Ghaffari, Shahrbano Rostami, Mahdi Jalili, Ahmad Reza Shamshiri, Ardeshir Ghavamzadeh
Journal: Blood (2009)
Primary hepatic lymphoma: a monoinstitutional experience
Authors: F. Crepaldi, B. Bocci, M. Blasi, C. Careri, D. Patanè, G. Viale, M. Violati, V. Bordin, C. Codecà, A. Moro, P. Foa, R. Santambrogio, D. Ferrari
Journal: Annals of Oncology (2016)